Insights
Insights From Our Experts
Articles
Seeing the Whole Picture: How Value & Evidence Generalists Drive Strategic Impact and Client Success
EVERSANA’s Powerful Matrix Approach to Value & Evidence EVERSANA’s Value & Evidence (V&E) team is comprised of seasoned HEOR researchers and industry experts who are collectively focused on improving healthcare outcomes and ultimately creating a healthier…
Identifying Challenges and Solutions for Indirect Comparisons in Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare condition characterized by muscle weakness due to reduced connectivity between nerves and muscles throughout the body. There are many newer treatments for gMG, but no clinical trials directly comparing…
Navigating the New HTA Landscape: Pamela Vo on Strategic Evidence Planning
The implementation of the EU Health Technology Assessment (HTA) regulation marks a pivotal shift in how clinical evidence is evaluated across Europe. With the regulation now in effect, pharmaceutical companies face both new opportunities and new…
Disrupting the Life Sciences Commercial Model: EVERSANA Joins Insightful Conference Sessions on AI & Patient-Centric Models
Industry Thought Leaders Shape Wharton Conference On September 26, 2025, thought leaders from EVERSANA and across the healthcare, technology and life sciences industries gathered at The Wharton School in Philadelphia to participate in an exclusive scenario…
Brave New Commercialization World: Reimagining Global Launch Strategies in Life Sciences
The pace of change in global healthcare is accelerating and nowhere is this more evident than in the commercialization of new therapies and medical devices. Traditional launch strategies simply can’t keep up. Here at EVERSANA, we’re…
Strategic PICO Planning: Navigating Oncology Markets with NAVLIN by EVERSANA
Strategic PICO Planning in Oncology Markets In today’s dynamic healthcare environment, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is critical to successful evidence generation. With evolving regulatory frameworks—like the European Joint Clinical Assessment (JCA)—now…
Strategic PICO Planning: Enhancing Early-Phase Development for Market Access
Future-Proofing Early Development with Strategic PICO Planning A global pharmaceutical company with a diverse pipeline needed to align early clinical planning with future market access requirements—before Phase II. With Target Product Profiles (TPPs) still in development,…
How AI & Automation Plays a Role in Powering the Future of Compliant Pharma Marketing
In the pharmaceutical industry, marketing isn’t just about creativity—it’s about compliance. Every campaign must navigate a maze of Medical, Legal, and Regulatory (MLR) reviews, FDA guidelines, and therapeutic accuracy. The stakes are high, and the margin…
AI in DTP: Turning Data into Meaningful Care Moments
In today’s healthcare landscape, personalization isn’t a luxury—it’s a necessity. In his latest article for Med Ad News, Hari Ramachandran, Executive Vice President, Direct-to-Patient Product Management at EVERSANA, explores how Artificial Intelligence is transforming Direct-to-Patient (DTP)…
Reimagining Pharma Commercialization with AI Agents
A Q&A with Imtiaz Samjoo, EVERSANA, and Kevin Kallmes, Nested Knowledge. EVERSANA and Nested Knowledge have teamed up to revolutionize systematic literature reviews (SLRs) using AI. Their collaboration is streamlining workflows and unlocking faster, more precise…